Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Arcutis Biotherapeutics's Enterprise Value is $3,309.2 Mil.
Arcutis Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $16.9 Mil. Therefore, Arcutis Biotherapeutics's EV-to-FCF for today is 195.63.
The historical rank and industry rank for Arcutis Biotherapeutics's EV-to-FCF or its related term are showing as below:
ARQT'
s EV-to-FCF Range Over the Past 10 Years
Min: -221.5 Med: -3.87 Max: 211.41
Current: 195.63
During the past 9 years, the highest EV-to-FCF of Arcutis Biotherapeutics was 211.41. The lowest was -221.50. And the median was -3.87.
ARQT's EV-to-FCF is ranked worse than 93% of 343
companies
in the Biotechnology industry
Industry Median: 14.79
vs ARQT: 195.63
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Arcutis Biotherapeutics's PE Ratio (TTM) for today is calculated as:
Arcutis Biotherapeutics's share price for today is $27.33.
Arcutis Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.034.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arcutis Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcutis Biotherapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Arcutis Biotherapeutics's EV-to-FCF falls into.
Arcutis Biotherapeutics's current Enterprise Value is $3,309.2 Mil.
Arcutis Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcutis Biotherapeutics (ARQT) has a EV-to-FCF of 195.63 as of Jul. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arcutis Biotherapeutics and its competitors. According to the industry distribution chart, Arcutis Biotherapeutics ranks #319 out of 343 companies in the Biotechnology industry, placing it in the top 93%.
Is Arcutis Biotherapeutics' EV-to-FCF too high?
Arcutis Biotherapeutics' current EV-to-FCF is 195.63. The Biotechnology industry median EV-to-FCF is 14.79. Arcutis Biotherapeutics' value of 195.63 is 1222.7% above this industry median. Based on the distribution chart, Arcutis Biotherapeutics ranks #319 out of 343 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arcutis Biotherapeutics has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arcutis Biotherapeutics' EV-to-FCF compare to IDYA and NAMS?
According to the Biotechnology industry distribution chart, Arcutis Biotherapeutics ranks #319 out of 343 companies for EV-to-FCF. This places Arcutis Biotherapeutics in the lower half of its industry. The industry median EV-to-FCF is 14.79. Arcutis Biotherapeutics' value of 195.63 is 1222.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.79, based on 343 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcutis Biotherapeutics's current EV-to-FCF of 195.63 is 1222.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Arcutis Biotherapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcutis Biotherapeutics's current EV-to-FCF is 195.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcutis Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Arcutis Biotherapeutics (ARQT) is currently considered Modestly Undervalued. The stock's GF Value™ is $30.79, compared to a current price of $27.33 — trading 11.2% below its estimated fair value. The current EV-to-FCF is 195.63 and 1222.7% above the Biotechnology industry median of 14.79. Arcutis Biotherapeutics' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Arcutis Biotherapeutics (ARQT), the current EV-to-FCF is 195.63 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcutis Biotherapeutics (ARQT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcutis Biotherapeutics stock appears to be undervalued.
The current stock price of $27.33 is trading 11.2% below its estimated GF Value™ of $30.79.
GuruFocus considers Arcutis Biotherapeutics to be Modestly Undervalued.
Key valuation signals for ARQT:
EV-to-FCF: 195.63
GF Value™: $30.79 vs. price of $27.33 (11.2% below fair value)
Industry Position: 1222.7% above the Biotechnology median (#319 of 343)
No single metric tells the full story. See the ARQT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
56GF Score
Get the complete analysis for ARQT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARQT has been successfully added to your 
